Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Kai Michael Beeh,1 Anne-Marie Kirsten,2 Ana-Maria Tanase,3 Alexia Richard,3 Weihua Cao,4 Bettina Hederer,3 Jutta Beier,1 Oliver Kornmann,5 Richard N van Zyl-Smit6 1Insaf Respiratory Research Institute Wiesbaden, Wiesbaden, Germany; 2Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway...

Full description

Bibliographic Details
Main Authors: Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN
Format: Article
Language:English
Published: Dove Medical Press 2018-12-01
Series:International Journal of COPD
Subjects:
COPD
once-daily inhalers
fixed-combination inhalers
indacaterol
mometasone
LABA/ICS combinations
Online Access:https://www.dovepress.com/indacaterol-acetatemometasone-furoate-provides-sustained-improvements--peer-reviewed-article-COPD

Internet

https://www.dovepress.com/indacaterol-acetatemometasone-furoate-provides-sustained-improvements--peer-reviewed-article-COPD

Similar Items